Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹211.39
1.76 (0.84%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹1.41K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
31.9
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹155+36.4%
52W High₹301.65-29.9%
Current Price
₹211.39
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹169.11
Upper Circuit₹253.67
Reference Price
₹211.39
Investment Checklist
Double Bottom on 1W (BREAKOUT CONFIRMED) — target ₹218.45
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹218.0
Trend: Price above all key MAs — strong uptrend
Composite score 53.94 (BUY) with 89.8% confidence
Golden Cross detected 5 day(s) ago
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
90%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend
EMA20
205.08
EMA50
201.34
EMA200
207.36
Price Action
MIXED
NEUTRAL
Higher Highs5
Higher Lows6
Lower Highs4
Lower Lows3
Support & Resistance Levels
Resistance (Above)
₹214.50
₹222.00
₹225.37
₹229.75
₹233.00
Support (Below)
₹210.54
₹208.00
₹204.95
₹201.50
₹199.00
Volume Analysis
TrendDECREASING
Change-53.80%
Unusual VolumeNo
Divergence Detected
Bearish (price up, volume down)
Recent MA Crossovers
Golden Cross
5 days ago
BUY
Stop Loss Levels
Fixed Risk
1% Risk₹209.28
3% Risk₹205.05
5% Risk₹200.82
7% Risk (Custom)
₹196.59Technical Levels
1x ATR (Volatility)₹203.85
2x ATR (Swing)₹196.31
3x ATR (Trend)₹188.77
Immediate Support₹210.54
Moving Averages
EMA 9 (Short-term)₹205.78
EMA 20 (Medium-term)₹205.08
EMA 50 (Trend)₹201.34
EMA 200 (Long-term)₹207.36
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹58.6 Cr | ₹75.6 Cr | ₹74.5 Cr | ₹72.9 Cr |
| Net Profit | ₹6.6 Cr | ₹10.8 Cr | ₹12.6 Cr | ₹11 Cr |
| EPS | — | ₹1.60 | ₹1.88 | ₹1.67 |
| Operating Profit | ₹11.2 Cr | ₹17 Cr | ₹19.5 Cr | ₹17.2 Cr |
ROE
23.07%
ROCE
28.38%
Debt/Equity
0.04
Current Ratio
6.22
OPM
23.53%
NPM
15.01%
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 04 May 2026 | Buy Back | BUYBACK |
| 12 Sept 2025 | Dividend - Rs 2.50 Per Share | DIVIDEND |
| 08 Jan 2025 | Face Value Split (Sub-Division) - From Rs 5/- Per Share To Rs 2/- Per Share | STOCK_SPLIT |
| 06 Sept 2024 | Dividend - Rs 5 Per Share | DIVIDEND |
| 21 Aug 2023 | Dividend - Rs 5 Per Share | DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for JAGSNPHARM
View AllNEWS
positive
Business Standard - Markets 92d ago
Board of Jagsonpal Pharmaceuticals approves shares buyback of Rs 40 cr
At meeting held on 12 March 2026
JAGSNPHARMHealthcare